Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Last Updated: June 7, 2023

Investigational Drug Information for Rilapladib

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

What is the development status for investigational drug Rilapladib?

Rilapladib is an investigational drug.

There have been 4 clinical trials for Rilapladib. The most recent clinical trial was a Phase 2 trial, which was initiated on October 1^st 2011.

The most common disease conditions in clinical trials are Atherosclerosis, Alzheimer Disease, and [disabled in preview]. The leading clinical trial sponsors are GlaxoSmithKline and [disabled in preview].

Summary for Rilapladib

US Patents	0
International Patents	0
US Patent Applications	162
WIPO Patent Applications	67
Japanese Patent Applications	19
Clinical Trial Progress	Phase 2 (2011-10-01)
Vendors	40

Recent Clinical Trials for Rilapladib

Title	Sponsor	Phase
Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Rilapladib (SB659032) in Healthy Volunteers	GlaxoSmithKline	Phase 1
A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's Disease	GlaxoSmithKline	Phase 2
An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks	GlaxoSmithKline	Phase 2

See all Rilapladib clinical trials

Clinical Trial Summary for Rilapladib

Top disease conditions for Rilapladib

Top clinical trial sponsors for Rilapladib

See all Rilapladib clinical trials

US Patents for Rilapladib

+ Get email alerts for changes to this table

Subscribe to access the full database, or Try a Trial
Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
>Drugname	>Patent Number	>Patent Title	>Patent Assignee	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

AstraZeneca

McKinsey

Dow

Express Scripts

Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.